Nine -valent HPV expansion: should be done in advance in advance

Author: Chen Ding

Recently, the WeChat signal of "Merck China" announced that its nine -valent papilloma virus vaccine (nine -valent HPV vaccine) has been approved by the National Drug Administration of China. Vaccinations have expanded to women 9 ~ 45 years old in China.

Since the nine -valent HPV vaccine has been listed in China in 2018, demand has been high. Until today, the nine -valent HPV is still "hard to find". Earlier, the vaccination scope of the vaccination was 16 to 26 years old. It is now allowed to be expanded by age, which will mean that more women who want to vaccinate the vaccine will inevitably exacerbate the nervous situation of the vaccine supply and cause the ox to sell it. Various problems appear.

The vast majority of Chinese vaccination is carried out in public medical institutions. Therefore, as a public service provider, medical institutions must do a good job of vaccination services in advance. This includes optimizing the vaccine appointment vaccination mechanism to avoid scalpel crowded resources. At the same time, it should continue to strengthen publicity and popularization, so that the wishes of women who are willing to understand the second -price and quadrilateral HPV vaccine can also prevent cervical cancer. In addition, because the nine -valent HPV aging is still in the paper operation stage and has not yet been implemented, the pharmaceutical regulatory department should also do a good job of transitional guidance in time to clearly allow the aging vaccination batches to facilitate the judgment of the medical institution to judge Execution, avoiding inconvenience of being willing to vaccinate people.

Source: Light Review

Picture: Xinhua News Agency

Responsible editor: Wang Zimo

Edit: Wu Yaqi, Sun Xiaoting, Wang Yuan

- END -